Merck & Co., Inc.
MRKHealthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −12.1%
- Free cash flow
- −19.3%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow MRK
Alert me
Merck & Co., Inc. (MRK) Operating cash flow
Merck & Co., Inc.'s operating cash flow for fiscal 2025 was $16.5B, down 23.3% from $21.5B in fiscal 2024. Over the twelve months to Sep 30, 2026 it was $18.7B. Over the past ten years it has ranged from $6.5B (fiscal 2017) to $21.5B (fiscal 2024); the current reading is higher than 82% of that period. Merck & Co., Inc. ranks 6th of 21 Drug Manufacturers General companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $16.5B | (23.27%) |
| FY2024 | $21.5B | 65.06% |
| FY2023 | $13.0B | (31.89%) |
| FY2022 | $19.1B | 45.52% |
| FY2021 | $13.1B | 72.27% |
| FY2020 | $7.6B | (14.26%) |
| FY2019 | $8.9B | (18.66%) |
| FY2018 | $10.9B | 69.31% |
| FY2017 | $6.5B | (37.83%) |
| FY2016 | $10.4B | (17.24%) |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $6.6B | 22.12% |
| Jun 2026 | $5.4B | 37.06% |
| Mar 2026 | $3.9B | 37.14% |
| Dec 2025 | $2.9B | (63.47%) |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| JNJ Johnson & Johnson compare | $26.2B |
| ABBV AbbVie Inc. compare | $20.1B |
| NVO Novo Nordisk A/S compare | $19.2B |
| MRK Merck & Co., Inc. | $18.7B |
| NVS Novartis AG compare | $17.3B |
| GILD Gilead Sciences, Inc. compare | $14.5B |
| PFE Pfizer Inc. compare | $14.2B |
| AZN AstraZeneca PLC compare | $13.2B |
| AMGN Amgen Inc. compare | $12.0B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on MRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement